Interleukin-17A facilitates tumor progression via upregulating programmed death ligand-1 expression in hepatocellular carcinoma

Figure 2 Interleukin-17A weakened the killing effect of T cells on hepatocellular carcinoma cells. A: Hepatocellular carcinoma cell proliferation and apoptosis were tested by flow cytometry after coculture with or without interleukin-17A (IL-17A) for 24 h. The number of T cells was ten times greater than the number of tumor cells; B: Histogram showing the percentage of proliferating and apoptotic hepatocellular carcinoma cells and the percentage of T cells in the coculture model; C: The expression of programmed death-1 on T cells in coculture models. ^aP < 0.05; ^bP < 0.01; ^cP< 0.001. APC-CD8-H: Allophycocyanin-cluster of differentiation 8-height; FITC-CFSE-H: Fluorescein isothiocyanate-carboxy fluorescein diacetate succinimidyl ester-height; FITC-PD1-H: Fluorescein isothiocyanate-programmed cell death 1-height; FSC-H: Forward scatter-height; PE-PI-H: Phycoerythrin-propidium iodide-height; SSC-H: Side scatter-height.